BSE: 524444
EVEXIA LIFECARE LIMITED
Trades in food ingredients, edible oil and other commodities, with the bulk of disclosed segment revenue sitting in an "Others" line that is not broken out. The latest disclosed segment split (year-to-date period ending 31 December 2018) puts Others at 57.4% of segment revenue, the Food & Ingredient Division at 29.6% and Edible Oil at 13.1%, with Securities, Manufacturing and Garment divisions contributing negligible amounts. Subsidiary Kavit Edible Oil Limited has been suspended since March 2015 and carries a negative net worth. FY26 consolidated revenue was Rs. 110.275 crore with a net profit of Rs. 1.6213 crore, translating to a 2.6% EBITDA margin and a 1.47% net profit margin. Operating cash flow for FY26 was deeply negative at Rs. -2,348.34 lakhs, and the statutory auditor issued a qualified opinion flagging recoverability of Rs. 735.13 lakhs of loans and Rs. 2,943.89 lakhs of trade receivables. Cost structure as disclosed is dominated by employee cost at 1.4% of revenue and other operating expenses at 1.2% of revenue, with capex at 2.9% of revenue. AR · MarketPing reader · 2026-08-03
Revenue streams, as the annual report describes them. Others (57%), Food & Ingredient Division (30%), Edible Oil (13%), Securities Division (0%). Thin-margin commodity and chemical trading company with a legacy, suspended edible oil subsidiary
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 76 | 70 | 56 | 110 | 110 |
| EBITDA (ex other income) | 2 | 1 | 2 | 4 | 3 |
| margin % | 3.2 | 0.8 | 3.5 | 3.7 | 2.6 |
| Owners' profit | 0 | 0 | 0 | 0 | 2 |
| EPS, as reported (₹) | 0.14 | 0.01 | 0.02 | 0.01 | 0.00 |
| ROE % · ROCE % | 1.1 · 2.4 | 0.7 · 0.3 | 1.1 · 0.3 | 0.2 · 0.3 | 0.4 · 0.3 |
| Debt / equity (x) | 0.07 | 7.80 | 5.30 | 0.83 | 0.01 |
| Cash from operations | (6) | (3) | 17 | 0 | (23) |
| Capex | (2) | (2) | 0 | (7) | (3) |
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 21 | 28 | 22 | 24 | 22 | 26 | 25 | 37 |
| Profit before tax | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 |
| Net profit | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 |
| EPS (₹) | 0.02 | 0.01 | 0.01 | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 |
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| UNIPHOS ENTERPRISES LTD | 592 | 29.3 | 0.24 | — | 0.8 | 0.8 | — | — |
| VINYL CHEMICALS (I) LTD. | 451 | 19.4 | 3.46 | — | 12.7 | 16.8 | — | 9.0 |
| BHAVIK ENTERPRISES LIMITED | 297 | 20.1 | — | — | — | 11.1 | — | — |
| EVEXIA LIFECARE LIMITED ◆ | 295 | 52.3 | 0.68 | 102.9 | 0.4 | 0.3 | 0.7 | 3.3 |
| SHANKAR LAL RAMPAL LTD | 259 | 14.0 | 2.11 | — | 11.0 | 14.7 | — | 9.4 |
| A-1 LIMITED | 238 | 21.5 | 4.40 | 22.2 | 11.1 | 14.8 | — | 3.5 |
| MYSORE PETRO CHEMICALS L | 78 | 48.9 | 0.35 | 83.9 | 0.4 | 0.2 | 18.0 | (0.4) |
| Yash Chemex Limited | 52 | 26.0 | 0.86 | 14.2 | 4.0 | 5.2 | 20.6 | (0.0) |
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 52.3 | 19.8 | 12 of 12 | 0% |
| P/B | 0.7 | 0.8 | 5 of 10 | 56% |
| ROCE | 0.3 | 3.0 | 10 of 14 | 31% |
| ROE | 0.4 | 0.8 | 7 of 10 | 33% |
| Debt / Equity | 0.0 | 0.0 | 5 of 10 | 56% |
| EBITDA margin | 3.3 | 3.3 | 5 of 9 | 50% |
| Revenue growth | 55.8 | 10.9 | 4 of 11 | 70% |
| Profit growth | 153.7 | 5.7 | 2 of 10 | 89% |
| Market cap | 295 | 78 | 4 of 13 | 75% |
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 27 Oct 2026 · Newspaper publication of September quarter unaudited results | compliance | minimal | — | — |
| 24 Oct 2026 · Q2 FY27 profit dips as auditor withholds review conclusion on receivables | results | high | — | — |
| 24 Oct 2026 · Consolidated Q2 revenue and profit fall; auditor cannot conclude on results | results | high | — | — |
| 19 Oct 2026 · Board meeting on Oct 24, 2026 to approve Q2 and H1 FY27 results | results | low | — | — |
| 13 Oct 2026 · Evexia Lifecare appoints Mr. Sagar Pagariya as Company Secretary | management changes | medium | — | — |
| 13 Oct 2026 · Evexia Lifecare appoints new Company Secretary and Compliance Officer | management changes | medium | — | — |
| 7 Oct 2026 · Routine filing of demat certificate under SEBI Reg 74(5) for Q2 FY27 | compliance | minimal | — | — |
| 5 Oct 2026 · All 10 resolutions passed at 35th AGM with over 99.9 percent approval | board shareholder meetings | low | — | — |
| 5 Oct 2026 · Promoter group Shree Saibaba Exim buys 0.35% stake in Evexia Lifecare | ownership changes | medium | — | — |
| 1 Oct 2026 · Promoter Group Shree Saibaba Exim buys 66.26 lakh shares via open market | ownership changes | high | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.